However, it is evident from what has been said so far that SGK1 is proposed as a therapeutic molecular target for a modern therapy of the depressive disorder and that efforts in this sense will increasingly clarify how much this new candidate gene can provide the explanations missing in the univocal vision of the disease. This evidence concerns the gene SGK1 and depressive disorder.